世界卫生组织更新用于解读结核病耐药突变的全球目录
正文 · 中文译文
世界卫生组织(WHO)今日发布了第三版《结核分枝杆菌复合群突变目录及其与耐药性的关联》,提供了迄今为止最全面的全球参考,用于解读与耐药结核病(TB)相关的基因组突变。 更新后的目录加强了结核病分子和测序耐药检测的证据基础,支持全球实验室、监测规划、诊断开发商和研究人员更一致地解读和使用基因组数据。 “快速准确地检测耐药性对于确保结核病患者尽早获得最有效的治疗至关重要,”WHO艾滋病、结核病、肝炎和性传播感染司司长Tereza Kasaeva博士说。“随着靶向下一代测序技术日益普及,第三版大幅扩展了可用于解读耐药性的全球证据,包括对新型和重新利用药物的证据,同时加强了指导,以支持基因组结果在实践中的一致应用。” 第三版已更新以: 纳入来自超过75个国家逾71000株临床结核分枝杆菌分离株的数据——与2023年发布的第二版相比,数据量和覆盖范围分别增加了37%和12%; 扩展了新型和重新利用抗结核药物(包括pretomanid和cycloserine)的证据; 纳入更新的生物信息学和统计学方法以改进突变分类; 引入增强的解释框架,其中分级突变列表与附加分级规则及其他解释标准一并应用,以支持对耐药性的适当解释; 提供强化的实用指导和新常见问题解答,以帮助用户理解、应用和实施该目录;以及 加强对基于测序的药物敏感性检测、分子诊断方法的开发与评估以及全球结核病耐药监测的支持。 结核病仍是全球主要的传染病致死原因。耐药结核病继续构成重大挑战,受影响者中接受治疗者不足二分之一,凸显了加强耐药性早期发现和获得照护的迫切需要。 第三版建立在世界卫生组织于2021年发布的首版突变目录和2023年发布的第二版基础之上,反映了国家结核病规划、超国家参考实验室、学术机构和技术伙伴之间持续的国际合作,以改进基因组耐药检测的证据基础。
正文 · 英文原文
The World Health Organization (WHO) today published the third edition of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, providing the most comprehensive global reference to date for interpreting genomic mutations associated with drug-resistant tuberculosis (TB). The updated catalogue strengthens the evidence base for molecular and sequencing-based drug resistance testing for TB, supporting more consistent interpretation and use of genomic data across laboratories, surveillance programmes, diagnostic developers and researchers worldwide. "Rapid and accurate detection of drug resistance is essential to ensuring that people with tuberculosis receive the most effective treatment as early as possible,” said Dr Tereza Kasaeva, Director of WHO’s Department for HIV, TB, Hepatitis and Sexually Transmitted Infections. “As targeted next-generation sequencing technologies become increasingly accessible, this third edition substantially expands the global evidence available for interpreting drug resistance, including for newer and repurposed medicines, while strengthening guidance to support the consistent application of genomic results in practice." The third edition has been updated to: include data from more than 71 000 clinical Mycobacterium tuberculosis isolates from over 75 countries – representing 37% and 12% increases in volume and coverage over the second edition that was published in 2023; expand evidence for newer and repurposed anti-TB medicines, including pretomanid and cycloserine; incorporate updated bioinformatic and statistical methods to improve mutation classification; introduce an enhanced interpretation framework in which the Graded Mutation List is applied together with additional grading rules and other interpretation criteria to support appropriate interpretation of drug resistance; provide strengthened practical guidance and new FAQs to support users in understanding, applying and implementing the catalogue; and strengthen support for sequencing-based drug susceptibility testing, the development and evaluation of molecular diagnostics, and global TB drug resistance surveillance. Tuberculosis remains a leading infectious disease killer worldwide. Drug-resistant TB continues to pose a major challenge, with fewer than one in two people affected accessing treatment, highlighting the urgent need to strengthen early detection of drug resistance and access to care. The third edition builds on the first WHO mutation catalogue, published in 2021, and the second edition released in 2023, reflecting continued international collaboration among national TB programmes, supranational reference laboratories, academic institutions and technical partners to improve the evidence base for genomic drug-resistance testing.